Cargando…

Bleeding Outcomes After Dental Extraction in Patients Under Direct-Acting Oral Anticoagulants vs. Vitamin K Antagonists: A Systematic Review and Meta-Analysis

Background: The current systematic review aimed to compare bleeding outcomes in dental extraction patients receiving uninterrupted Direct-acting oral anticoagulant (DOAC) or Vitamin K antagonists (VKAs) for various systemic diseases. Methods: PubMed, Embase, ScienceDirect, CENTRAL, and Google Schola...

Descripción completa

Detalles Bibliográficos
Autores principales: Hua, Wenbing, Huang, Zhengmei, Huang, Zhuoli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585494/
https://www.ncbi.nlm.nih.gov/pubmed/34776943
http://dx.doi.org/10.3389/fphar.2021.702057
_version_ 1784597703318044672
author Hua, Wenbing
Huang, Zhengmei
Huang, Zhuoli
author_facet Hua, Wenbing
Huang, Zhengmei
Huang, Zhuoli
author_sort Hua, Wenbing
collection PubMed
description Background: The current systematic review aimed to compare bleeding outcomes in dental extraction patients receiving uninterrupted Direct-acting oral anticoagulant (DOAC) or Vitamin K antagonists (VKAs) for various systemic diseases. Methods: PubMed, Embase, ScienceDirect, CENTRAL, and Google Scholar databases were searched for randomized controlled trials, controlled clinical trials, prospective and retrospective cohort studies, and case control studies, conducted on adult patients undergoing dental extraction under uninterrupted DOAC or VKAs therapy and reporting bleeding outcomes. The search was conducted up to March 31, 2021. We pooled data to calculate risk ratios (RR) with 95% confidence intervals (CI) in a random-effects model. Results: Eight studies comparing 539 patients on DOAC therapy and 574 patients on VKAs were included. Meta-analysis indicated a statistically significant lower bleeding risk in patients under DOAC therapy (RR 0.68 95% CI 0.49, 0.95 I(2) = 0%). However, on sensitivity analysis, the results were statistically non-significant after exclusion of any of the included studies. On pooled analysis of limited number of studies, we found no statistically significant difference in the risk of bleeding between apixaban (RR 0.85 95% CI 0.45, 1.60 I(2) = 0%), rivaroxaban (RR 0.95 95% CI 0.36, 2.48 I(2) = 45%), dabigatran (RR 0.49 95% CI 0.19, 1.28 I(2) = 5%), edoxaban (RR 0.41 95% CI 0.13, 1.27 I(2) = 0%) and VKAs. Conclusion: The results of the first review comparing bleeding outcomes after dental extraction in patients on uninterrupted DOAC or VKA therapy indicates that patients on DOAC may have a reduced risk of hemorrhage. Current evidence is of very low-quality and should be interpreted with caution. Data on individual DOAC is scarce and at this point, the difference in the risk of bleeding between these drugs cannot be elucidated. Further studies with a large sample size shall supplement our conclusion.
format Online
Article
Text
id pubmed-8585494
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85854942021-11-12 Bleeding Outcomes After Dental Extraction in Patients Under Direct-Acting Oral Anticoagulants vs. Vitamin K Antagonists: A Systematic Review and Meta-Analysis Hua, Wenbing Huang, Zhengmei Huang, Zhuoli Front Pharmacol Pharmacology Background: The current systematic review aimed to compare bleeding outcomes in dental extraction patients receiving uninterrupted Direct-acting oral anticoagulant (DOAC) or Vitamin K antagonists (VKAs) for various systemic diseases. Methods: PubMed, Embase, ScienceDirect, CENTRAL, and Google Scholar databases were searched for randomized controlled trials, controlled clinical trials, prospective and retrospective cohort studies, and case control studies, conducted on adult patients undergoing dental extraction under uninterrupted DOAC or VKAs therapy and reporting bleeding outcomes. The search was conducted up to March 31, 2021. We pooled data to calculate risk ratios (RR) with 95% confidence intervals (CI) in a random-effects model. Results: Eight studies comparing 539 patients on DOAC therapy and 574 patients on VKAs were included. Meta-analysis indicated a statistically significant lower bleeding risk in patients under DOAC therapy (RR 0.68 95% CI 0.49, 0.95 I(2) = 0%). However, on sensitivity analysis, the results were statistically non-significant after exclusion of any of the included studies. On pooled analysis of limited number of studies, we found no statistically significant difference in the risk of bleeding between apixaban (RR 0.85 95% CI 0.45, 1.60 I(2) = 0%), rivaroxaban (RR 0.95 95% CI 0.36, 2.48 I(2) = 45%), dabigatran (RR 0.49 95% CI 0.19, 1.28 I(2) = 5%), edoxaban (RR 0.41 95% CI 0.13, 1.27 I(2) = 0%) and VKAs. Conclusion: The results of the first review comparing bleeding outcomes after dental extraction in patients on uninterrupted DOAC or VKA therapy indicates that patients on DOAC may have a reduced risk of hemorrhage. Current evidence is of very low-quality and should be interpreted with caution. Data on individual DOAC is scarce and at this point, the difference in the risk of bleeding between these drugs cannot be elucidated. Further studies with a large sample size shall supplement our conclusion. Frontiers Media S.A. 2021-10-28 /pmc/articles/PMC8585494/ /pubmed/34776943 http://dx.doi.org/10.3389/fphar.2021.702057 Text en Copyright © 2021 Hua, Huang and Huang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Hua, Wenbing
Huang, Zhengmei
Huang, Zhuoli
Bleeding Outcomes After Dental Extraction in Patients Under Direct-Acting Oral Anticoagulants vs. Vitamin K Antagonists: A Systematic Review and Meta-Analysis
title Bleeding Outcomes After Dental Extraction in Patients Under Direct-Acting Oral Anticoagulants vs. Vitamin K Antagonists: A Systematic Review and Meta-Analysis
title_full Bleeding Outcomes After Dental Extraction in Patients Under Direct-Acting Oral Anticoagulants vs. Vitamin K Antagonists: A Systematic Review and Meta-Analysis
title_fullStr Bleeding Outcomes After Dental Extraction in Patients Under Direct-Acting Oral Anticoagulants vs. Vitamin K Antagonists: A Systematic Review and Meta-Analysis
title_full_unstemmed Bleeding Outcomes After Dental Extraction in Patients Under Direct-Acting Oral Anticoagulants vs. Vitamin K Antagonists: A Systematic Review and Meta-Analysis
title_short Bleeding Outcomes After Dental Extraction in Patients Under Direct-Acting Oral Anticoagulants vs. Vitamin K Antagonists: A Systematic Review and Meta-Analysis
title_sort bleeding outcomes after dental extraction in patients under direct-acting oral anticoagulants vs. vitamin k antagonists: a systematic review and meta-analysis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585494/
https://www.ncbi.nlm.nih.gov/pubmed/34776943
http://dx.doi.org/10.3389/fphar.2021.702057
work_keys_str_mv AT huawenbing bleedingoutcomesafterdentalextractioninpatientsunderdirectactingoralanticoagulantsvsvitaminkantagonistsasystematicreviewandmetaanalysis
AT huangzhengmei bleedingoutcomesafterdentalextractioninpatientsunderdirectactingoralanticoagulantsvsvitaminkantagonistsasystematicreviewandmetaanalysis
AT huangzhuoli bleedingoutcomesafterdentalextractioninpatientsunderdirectactingoralanticoagulantsvsvitaminkantagonistsasystematicreviewandmetaanalysis